A Phase 3 interventional study of Abatacept in Active Polyarticular Juvenile Idiopathic Arthritis, sponsored by Bristol-Myers Squibb. Completed at 57 sites in 12 countries. Open to participants aged 2 Years to 17 Years. Per ClinicalTrials.gov, last updated 2023-07-12.
Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 109 studies in Arthritis, Juvenile with a site in United States — 20 open to participants now, 23 under way, 5 of them phase 3. Arthritis, Juvenile · United States.
Among the 109 studies in Arthritis, Juvenile with a site in United States, this one is the 8th largest by enrollment of the 83 interventional ones that give a count, is one of 9 that started in 2013, is one of 30 in phase 3, and was the 55th registered.
366 studies on the registry are indexed under Arthritis, Juvenile; 101 are open to participants now.
Browse Arthritis, Juvenile studies →20 of the 109 studies in Arthritis, Juvenile with a site in United States are open now. Recruiting first, the newest first:
Children's Hospital Medical Center, Cincinnati · Sites in United States
Ages up to 35
Children's Hospital Medical Center, Cincinnati · Sites in United States
Ages 14–26
Duke University · Sites in United States, Germany, Italy and 1 more country
Ages 2–21
NYU Langone Health · Sites in United States
Ages 18+
Novartis Pharmaceuticals · Sites in United States, Canada, France and 5 more countries
Ages 1+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 69 Arthritis, Juvenile studies recruiting now, 13 (19%) set no upper age limit and 50 (72%) stop at 75 or younger; 65 take children under 18; 11 take healthy volunteers.
This study: 2 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
109 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 18 · Phase 2 18 · Phase 3 32 · Phase 4 7
First in 1994; this study’s year is marked. 9 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 219 is above the median of 52 across 230 interventional studies indexed under Arthritis, Juvenile.
Median enrollment 55 across the 83 interventional studies, 288 across the 24 observational. Of the 75 that completed or were terminated, 46 (61%) have results posted.
This tab as a report to print or save as PDF → With an account.
56 of 109 have an industry lead sponsor. The 10 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
Bristol-Myers Squibb has 6 studies filed under Arthritis, Juvenile — fewer than ten, so there is no comparison to draw.
2 of the studies in Arthritis, Juvenile with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01962415Paul SzabolcsReduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT | 2026-11 |
| NCT07203001Novartis PharmaceuticalsA Phase II Trial to Evaluate the Clinical Efficacy, Safety and Tolerability of MAS825 in Pediatric and Adult Participants With Still's Disease | 2027-04-22 |
Add all 2 to your calendar (.ics) → With an account.
Among the 109 studies in Arthritis, Juvenile with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to estimate Abatacept steady-state trough concentration (Cmin) at Day 113 in children and adolescents with pJIA
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Short Term: Orencia 50 mg/mL, 87.5 mg/mL, 125 mg/mL pre-filled syringes subcutaneously (0.4 mL/0.7 mL/1.0 mL) weekly for 4 months Long term: Orencia 50 mg/mL, 87.5 mg/mL, 125 mg/mL pre-filled syringes subcutaneously (0.4 mL/0.7 mL/1.0 mL) weekly for 20 months
Biological: Abatacept
Also known as: Orencia
Abatacept Trough Concentration (Cmin) in Participants Ages 6 to 17
Trough concentration of abatacept (reported as geometric mean of Cmin) in all pharmacokinetic (PK)-evaluable participants. Cmin is reported in microgram per milliliter (µg/mL). Desired target therapeutic Cmin should be \>= 10 µg/mL.
Time frame: Day 113
Percentage of Participants (Ages 6 to 17) Achieving American College of Rheumatology Pediatric 30 Response (ACRp30)
ACRp30 is defined as ≥30% improvement in at least 3 of the 6 juvenile idiopathic arthritis (JIA) core set variables: 1. number of active joints 2. number of joints with limitation of motion (LOM) 3. physician global assessment of disease activity 4. parent global assessment of patient overall well-being 5. functional ability as measured by the Children's Health Assessment Questionnaire (CHAQ) 6. C-reactive protein (CRP). In addition to the above condition, to be considered a responder participants cannot have ≥30% worsening in more than 1 of the 3 remaining JIA core set variables for which improvement was not observed.
Time frame: Day 113
Abatacept Trough Concentration (Cmin) in Participants Ages 6 to 17 by Weight Tier Dose
Evaluation of the trough concentration of abatacept (reported as geometric mean of Cmin) in all pk-evaluable participants at Days 57, 85 and 113. Weight-tiered dosing groups are based on the first dose the participant received. Cmin is reported in microgram per milliliter (µg/mL). Here 'n' number analyzed signifies participants who were evaluable for each time point.
Time frame: Days 57, 85 and 113
Number of Participants With Adverse Events (AEs), Deaths, Serious AEs (SAEs) and AEs Leading to Discontinuation in the Short-Term Period for the 6-17 Year Age-Group Cohort
An AE is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation subject administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (such as an abnormal laboratory finding), symptom, or disease temporally associated with the use of investigational product, whether or not considered related to the investigational product. A SAE is any untoward medical occurrence that at any dose which results in death, is life threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect.
Time frame: From first dose up to 56 days post last dose in the short-term period (initial 4-month treatment period)
Number of Participants With Adverse Events (AEs), Deaths, Serious AEs and AEs Leading to Discontinuation in the Cumulative Period
An AE is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation subject administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (such as an abnormal laboratory finding), symptom, or disease temporally associated with the use of investigational product, whether or not considered related to the investigational product. A SAE is any untoward medical occurrence that at any dose which results in death, is life threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect.
Time frame: From first dose up to 56 days after last dose ( up to approximately 2 years)
Number of Participants With Positive Immunogenicity Response in the Short-Term Period for the 6-17 Year Age-Group Cohort
Overall number of participants with either a positive immunogenicity response for 'CTLA4 and possibly Ig' or 'Ig and/or Junction Region' relative to baseline. Sample draws for immunogenicity were scheduled at specific study days while on treatment for all subjects and at follow-up visits 28, 85, and 168 days after the last abatacept dose for those subjects who discontinued from the short term (ST) period (initial 4-month treatment period) or completed the ST study without continuing abatacept treatment.
Time frame: From first dose up to start of LT (for those continuing in long-term) or up to 168 days after the lost dose of study medication in the ST period (for those not entering in the long-term)
Number of Participants With Positive Immunogenicity Response in the Cumulative Period
Overall number of participants with either a positive immunogenicity response for 'CTLA4 and possibly Ig' or 'Ig and/or Junction Region' relative to baseline. Sample draws for immunogenicity were scheduled at specific study days while on treatment for all subjects and at follow-up visits 28, 85, and 168 days after the last abatacept dose regardless of whether they discontinued early in the short term (ST) or long term (LT) period, elected not to enter the LT period, or completed both ST and LT periods.
Time frame: From first dose up to 6 months following treatment discontinuation (up to approximately 2 years)
| Milestone | SC Abatacept Ages 6 to 17 | SC Abatacept Ages 2 to 5 |
|---|---|---|
| Started | 173 | 46 |
| Completed | 132 | 39 |
| Not completed | 41 | 7 |
| Withdrew: Adverse event | 7 | 1 |
| Withdrew: Lack of efficacy | 17 | 5 |
| Withdrew: Participant's request to discontinue | 4 | 1 |
| Withdrew: Poor/non-compliance | 1 | 0 |
| Withdrew: No longer met study criteria | 2 | 0 |
| Withdrew: Withdrawal by subject | 9 | 0 |
| Withdrew: Pregnancy | 1 | 0 |
Trough concentration of abatacept (reported as geometric mean of Cmin) in all pharmacokinetic (PK)-evaluable participants. Cmin is reported in microgram per milliliter (µg/mL). Desired target therapeutic Cmin should be \>= 10 µg/mL.
| µg/mL | SC Abatacept Ages 6 to 17 |
|---|---|
| Abatacept Trough Concentration (Cmin) in Participants Ages 6 to 17 | 39.7 ± 35 |
ACRp30 is defined as ≥30% improvement in at least 3 of the 6 juvenile idiopathic arthritis (JIA) core set variables: 1. number of active joints 2. number of joints with limitation of motion (LOM) 3. physician global assessment of disease activity 4. parent global assessment of patient overall well-being 5. functional ability as measured by the Children's Health Assessment Questionnaire (CHAQ) 6. C-reactive protein (CRP). In addition to the above condition, to be considered a responder participants cannot have ≥30% worsening in more than 1 of the 3 remaining JIA core set variables for which improvement was not observed.
| Percentage of participants | SC Abatacept Ages 6 to 17 |
|---|---|
| Percentage of Participants (Ages 6 to 17) Achieving American College of Rheumatology Pediatric 30 Response (ACRp30) | 83.2 (77.7 to 88.8) |
Evaluation of the trough concentration of abatacept (reported as geometric mean of Cmin) in all pk-evaluable participants at Days 57, 85 and 113. Weight-tiered dosing groups are based on the first dose the participant received. Cmin is reported in microgram per milliliter (µg/mL). Here 'n' number analyzed signifies participants who were evaluable for each time point.
| microgram per milliliter (µg/mL) | 10 to <25 kg Dosing Group | 25 to <50 kg Dosing Group | >=50 kg Dosing Group |
|---|---|---|---|
| Day 57 | 29.5 ± 32 | 36.2 ± 35 | 33.0 ± 33 |
| Day 85 | 27.7 ± 38 | 42.5 ± 32 | 36.0 ± 40 |
| Day 113 | 34.3 ± 39 | 44.2 ± 34 | 36.6 ± 31 |
An AE is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation subject administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (such as an abnormal laboratory finding), symptom, or disease temporally associated with the use of investigational product, whether or not considered related to the investigational product. A SAE is any untoward medical occurrence that at any dose which results in death, is life threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect.
| Participants | SC Abatacept Ages 6 to 17 |
|---|---|
| Deaths | 0 |
| SAEs | 5 |
| Drug-Related SAEs | 1 |
| Discontinuation due to SAEs | 2 |
| Overall AEs | 102 |
| Drug-Related AEs | 36 |
| Discontinuation due to AEs | 3 |
An AE is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation subject administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (such as an abnormal laboratory finding), symptom, or disease temporally associated with the use of investigational product, whether or not considered related to the investigational product. A SAE is any untoward medical occurrence that at any dose which results in death, is life threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect.
| Participants | SC Abatacept Ages 6 to 17 | SC Abatacept Ages 2 to 5 |
|---|---|---|
| Deaths | 0 | 0 |
| SAEs | 14 | 5 |
| Drug-Related SAEs | 1 | 2 |
| Discontinuation Due to SAEs | 4 | 0 |
| Overall AEs | 152 | 44 |
| Treatment-Related AEs | 54 | 30 |
| Discontinuation Due to AEs | 7 | 1 |
Overall number of participants with either a positive immunogenicity response for 'CTLA4 and possibly Ig' or 'Ig and/or Junction Region' relative to baseline. Sample draws for immunogenicity were scheduled at specific study days while on treatment for all subjects and at follow-up visits 28, 85, and 168 days after the last abatacept dose for those subjects who discontinued from the short term (ST) period (initial 4-month treatment period) or completed the ST study without continuing abatacept treatment.
| Participants | SC Abatacept Ages 6 to 17 |
|---|---|
| Number of Participants With Positive Immunogenicity Response in the Short-Term Period for the 6-17 Year Age-Group Cohort | 3 |
Overall number of participants with either a positive immunogenicity response for 'CTLA4 and possibly Ig' or 'Ig and/or Junction Region' relative to baseline. Sample draws for immunogenicity were scheduled at specific study days while on treatment for all subjects and at follow-up visits 28, 85, and 168 days after the last abatacept dose regardless of whether they discontinued early in the short term (ST) or long term (LT) period, elected not to enter the LT period, or completed both ST and LT periods.
| Participants | SC Abatacept Ages 6 to 17 | SC Abatacept Ages 2 to 5 |
|---|---|---|
| Number of Participants With Positive Immunogenicity Response in the Cumulative Period | 8 | 7 |
Collected over Participants were assessed for All-Cause Mortality from the date of their randomization until study completion (assessed up to approximately 113 months). SAEs and Other AEs were assessed from first dose to 168 days after last dose of study therapy (assessed up to approximately 113 months).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| SC Abatacept Ages 6 to 17 | 0/173 (0%) | 18/173 (10.4%) | 127/173 (73.4%) |
| SC Abatacept Ages 2 to 5 | 0/46 (0%) | 6/46 (13%) | 44/46 (95.7%) |
| Event | SC Abatacept Ages 6 to 17 | SC Abatacept Ages 2 to 5 |
|---|---|---|
| TachycardiaCardiac disorders | 0/173 | 1/46 |
| Abscess limbInfections and infestations | 0/173 | 1/46 |
| CellulitisInfections and infestations | 0/173 | 1/46 |
| Molluscum contagiosumInfections and infestations | 0/173 | 1/46 |
| Hand fractureInjury, poisoning and procedural complications | 0/173 | 1/46 |
| Limb injuryInjury, poisoning and procedural complications | 0/173 | 1/46 |
| OverdoseInjury, poisoning and procedural complications | 0/173 | 1/46 |
| Tendon disorderMusculoskeletal and connective tissue disorders | 0/173 | 1/46 |
| Febrile convulsionNervous system disorders | 0/173 | 1/46 |
| Erythema multiformeSkin and subcutaneous tissue disorders | 0/173 | 1/46 |
| Event | SC Abatacept Ages 6 to 17 | SC Abatacept Ages 2 to 5 |
|---|---|---|
| NasopharyngitisInfections and infestations | 63/173 | 20/46 |
| PyrexiaGeneral disorders | 22/173 | 15/46 |
| Upper respiratory tract infectionInfections and infestations | 37/173 | 12/46 |
| CoughRespiratory, thoracic and mediastinal disorders | 10/173 | 12/46 |
| GastroenteritisInfections and infestations | 19/173 | 9/46 |
| RhinitisInfections and infestations | 13/173 | 8/46 |
| NauseaGastrointestinal disorders | 21/173 | 7/46 |
| VomitingGastrointestinal disorders | 13/173 | 7/46 |
| HeadacheNervous system disorders | 25/173 | 7/46 |
| Abdominal painGastrointestinal disorders | 16/173 | 6/46 |
All treated population included all participants who received at least one dose of study medication.
| Age, Categorical(Participants) | SC Abatacept Ages 6 to 17 | SC Abatacept Ages 2 to 5 | Total |
|---|---|---|---|
| <=18 years | 173 | 46 | 219 |
| Between 18 and 65 years | 0 | 0 | 0 |
| >=65 years | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | SC Abatacept Ages 6 to 17 | SC Abatacept Ages 2 to 5 | Total |
|---|---|---|---|
| Female | 136 | 28 | 164 |
| Male | 37 | 18 | 55 |
| Race/Ethnicity, Customized(Participants) | SC Abatacept Ages 6 to 17 | SC Abatacept Ages 2 to 5 | Total |
|---|---|---|---|
| Black or African American | 14 | 1 | 15 |
| White | 144 | 44 | 188 |
| More than one race | 0 | 0 | 0 |
| Other | 15 | 1 | 16 |
| Weight(Participants) | SC Abatacept Ages 6 to 17 | SC Abatacept Ages 2 to 5 | Total |
|---|---|---|---|
| <25 kg | 18 | 43 | 61 |
| 25 to 50 kg | 74 | 3 | 77 |
| >=50 kg | 81 | 0 | 81 |
Ran from Aug 2013 to primary completion in Mar 2015, 18 months.
Results were first posted in Mar 2016, 1 year after primary completion.
Of 36 phase 3 interventional studies under Arthritis, Juvenile, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 70. This study's 18 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Abatacept